Dexcom G7 Now Covered Under Ontario Drug Benefit (ODB) Program
As of July 31, 2025, Dexcom G7 sensors and receivers will be officially listed under the Ontario Drug Benefit (ODB) program. This milestone expands access to real-time continuous glucose monitoring (rtCGM) for eligible Ontarians who manage their diabetes with insulin.
Who Is Eligible?
To qualify for Dexcom G7 coverage under ODB, individuals must meet the following criteria:
- Be a resident of Ontario with a valid Ontario Health Insurance Plan (OHIP) card.
- Be eligible for one of the ODB subplans (listed below).
- Use any type of insulin—no restrictions on insulin type or diabetes type.
- Have a prescription for Dexcom G7 written by a physician or nurse practitioner.
ODB Subplan Eligibility
Coverage is accessed through one of the following ODB subplans:
| ODB Plan | Eligibility | Patient Out-of-pocket Cost |
| Seniors Program | Age 65+ | $100 annual deductible, then standard co-pay per prescription. Low-income seniors may apply to qualify for waived fees. |
| Home and Community Care / LTC Homes | Residents in care facilities | Fully covered. No deductible or co-pay. |
| OHIP+ | Age 24 or under without private insurance | Fully covered, no co-pay. |
| Ontario Works / ODSP | Income of disability support recipients | Automatically covered. $2 co-pay per prescription. No deductible. |
| Trillium Drug Program | High drug costs relative to income | Deductible based on income. |
How to Access Dexcom G7 Through ODB
- Patients will need a valid prescription from a physician or nurse practitioner.
- Patients then simply bring their prescription to an Ontario pharmacy.
- No prior approval, LU codes, or forms are required.
Duration of Coverage & Quantity Limits
Coverage remains in place for as long as the patient is eligible under ODB and is using any insulin (including once daily or weekly insulin). A three-month supply may be dispensed at once, reducing co-pay frequency. There is a limit of forty-five Dexcom G7 Sensors per eligible patient for each 365-day period. Dexcom G7 Receivers are also covered by ODB if the patient does not have a compatible smart device.†
Summary of Coverage Options for Dexcom G7
Dexcom G7 is now publicly and privately reimbursed for individuals on insulin through the following programs:
- Ontario Drug Benefit (ODB) – for eligible residents living with diabetes on insulin.
- Assistive Devices Program (ADP) – for individuals with type 1 diabetes who meet ADP eligibility criteria.‡
- Non-Insured Health Benefits (NIHB) – for eligible First Nations and Inuit people living with diabetes on insulin.
- Private Insurance – most major insurers (e.g., Green Shield, Manulife, Sun Life) cover Dexcom G7 for individuals on insulin, with varying reimbursement models.
Choosing rtCGM: More Effective Diabetes Management for People Using Insulin
Clinical evidence supports the use of rtCGM for any individual living with diabetes on insulin. Significant clinical benefits include improved A1C, reduced incidence of hypoglycemia, and increased time in range (TIR).1-6
A recent clinical study involving individuals living with type 2 diabetes (T2D) on non-intensive basal insulin therapy also demonstrated that rtCGM, such as Dexcom G7 can6:
- Help reduce emotional stress associated with diabetes.
- Improve perceived control.
- Foster greater confidence in self-management.
The American Diabetes Association’s 2025 Standards of Care also now recommends rtCGM for people living with type 2 diabetes—highlighting the value of systems like Dexcom G7 in improving diabetes management and quality of life for those using insulin.
With expanded coverage in Ontario and growing support nationwide, healthcare providers can confidently prescribe Dexcom G7—the most accurate rtCGM system in Canada.*,7 Now might be the time to consider the patients in your practice who qualify for coverage and could benefit from rtCGM technology.
*When compared with CGM systems commercially available in Canada as of November 2023.
† Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility.
‡ For complete eligibility criteria visit www.dexcom.com/en-CA/coverage/ontario-provincial-cgm-coverage
1 Beck RW, et al. JAMA. 2017;317(4):371-378.
2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
3 Martens T, et al. JAMA. 2021;325(22):2262-2272.
4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.
5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.
6 Crawford MA, et al. Diabetes. 2023;72(Suppl 1):677-P.
7 Dexcom, data on file, 2024.